Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.

Trial Details

NCT ID
NCT07145255
Phase
PHASE1 / PHASE2
Sponsor
MBrace Therapeutics
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • ADC
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Irving, Texas, United States|32.81402,-96.94889
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Provide written consent on an informed consent form (ICF), approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prio…
  • 18 years of age or older at the time of informed consent.
  • Female patients must be at least 2 years postmenopausal (defined as 2 years without menses), surgically sterile (at least 6 months prior to dosing;…
  • Must be nonlactating and have a negative serum (preferred) or urine pregnancy test results within 72 hours prior to the first dose of MBRC-201.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →